Serum estradiol concentration as measured by HPLC-RIA and bone mineral density in postmenopausal women during hormone replacement therapy

Hormone Research

Volumn 61, Issue 3, 2004, Pages 117-125

  Yasui, Toshiyuki ^a   Uemura, Hirokazu ^a   Umino, Yuka ^a   Takikawa, Masaya ^a   Kuwahara, Akira ^a   Saito, Seiichiro ^a   Matsuzaki, Toshiya ^a   Maegawa, Masahiko ^a   Furumoto, Hiroyuki ^a   Miura, Masakazu ^b   Irahara, Minoru ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b LSI MEDIENCE CORPORATION   (Japan)

Author keywords

Bone; Estradiol; Hormone replacement therapy

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZATION;

ADULT; AGED; BONE DENSITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); ESTRONE; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; RADIOIMMUNOASSAY; SPINE;

EID: 12144289071     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075523     Document Type: Article

References (31)

1. Lindsay R, Hart DM, Clark HD: The minimum effective dose of estrogen for the prevention of post-menopausal bone loss. Obstet Gynecol 1984;63:759-763.
2. Ravnikar VA: Compliance with hormone therapy. Am J Obstet Gynecol 1987;156:1332-1334.
3. Ettinger B, Pressman A, Silver P: Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause 1999;6:282-289.
4. Rossouw JE, Anderson GL, Prentice RL, et al, Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
5. Lobo RA, Whitehead MI: Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable? Climacteric 2001;4:110-119.
6. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Picker JH: Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-1079.
7. Archer DF, Dorin M, Lewis V, Schneider DL, Picker JH: Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080-1087.
8. Lobo RA, Bush T, Carr BR, Picker JH: Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001;76:13-23.
9. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH: Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-461.
10. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH: Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668-2676.
11. Genant HK, Lucas J, Weiss S, Akin M, Emkey R, McNaney-Flint H, Downs R, Mortola J, Watts N, Yang HM, Banav N, Brennan JJ, Nolan JC: Low-dose esterified estrogen therapy. Arch Intern Med 1997;157:2607-2615.
12. Yasui T, Yamada M, Kinoshita H, Uemura H, Yoneda N, Irahara M, Aono T, Sunahara S, Mito Y, Kurimoto F, Hata K: Combination of automatic HPLC-RIA method for determination of estrone and estradiol in serum. J Clin Lab Anal 1999;13:266-272.
13. Barbieri RL: Hormone treatment of endometriosis: The estrogen threshold hypothesis. Am J Obstet Gynecol 1992;166:740-745.
14. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd H: Biologic effects of transdermal estradiol. N Engl J Med 1986;314:1615-1620.
15. Yasui T, Uemura H, Tezuka M, Yamada M, Irahara M, Miura M, Aono T: Biological effects of hormone replacement therapy in relation to serum estradiol levels. Horm Res 2001;56:38-44.
16. Ettinger B, Genant HK, Cann CE: Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 1987;106:40-45.
17. Webber CE, Blake JM, Chambers LF, Roberts JG: Effects of 2 years of hormone replacement upon bone mass, serum lipids and lipoproteins. Maturitas 1994;19:13-23.
18. Mizunuma H, Okano H, Soda M, Kagami I, Miyamoto S, Tokizawa T, Honjo S, Ibuki Y: Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: A 2-year prospective study. Maturitas 1997;27:69-76.
19. Recker RR, Davies KM, Dowd RM, Heaney RP: The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. Ann Intern Med 1999;130:897-904.
20. Gass M, Liu J, Rebar RW: The effect of lowdose conjugated equine estrogens and cyclic MPA on bone density. Maturitas 2002;41:143-147.
21. Greendale GA, Wells B, Marcus R, Barrett-Connor E: How many women lose bone mineral density while taking hormone replacement therapy? Arch Intern Med 2000;160:3065-3071.
22. Rico H, Arribas I, Casanova FJ, Duce AM, Hernandez ER Cortes-Prieto J: Bone mass, bone metabolism, gonadal status and bone mass index. Osteoporosis Int 2002;13:379-387.
23. Stone K, Bauer DC, Black DM, Sklarin P, Ensrud KE, Cummings SR: Hormonal predictors of bone loss in elderly women: A prospective study. J Bone Miner Res 1998;13:1167-1174.
24. Walsh BW, Schiff I, Rosner B, Greemberg L, Ravnikar V, Sacks FM: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-1204.
25. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B: Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 1998;339:733-738.
26. Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR: Associations between low levels of serum estradiol, bone density, and fractures among elderly women: The study of osteoporotic fractures. J Clin Endocrinol Metab 1998;83:2239-2243.
27. Prestwood KM, Thompson DL, Kenny AM, Seibel MJ, Pilbeam CC, Raisz LG: Low dose estrogen and calcium have an additive effect on bone resorption in older women. J Clin Endocrinol Metab 1999;84:179-183.
28. Mei J, Yeung SSC, Kung AWC: High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab 2001;86:5217-5221.
29. Lobo RA, Nguyen HN, Eggena P, Brenner PF: Biological effects of equilin sulfate in postmenopausal women. Fertil Steril 1988;49:234-238.
30. Baracat E, Haidar M, Lopez FJ, Pickar J, Dey M, Negro-Vilar A: Estrogen activity and novel tissue selectivity of delta 8,9-dehydroestrone sulfate in postmenopausal women. J Clin Endocrinol Metab 1999;84 : 2020-2027.
31. The writing group for the PEPI trial: Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;276:1389-1396.